Posted by Michael Wonder on 11 May 2017
European Commission approves the only immunotherapy for high-risk neuroblastoma, bringing hope to thousands of children affected by a rare and devastating form of cancer
9 May 2017 - EUSA Pharma today announced that the European Commission has approved the antibody ch14.18/CHO, dinutuximab beta, for the treatment of high-risk neuroblastoma in patients aged 12 months and above.
Today’s announcement makes dinutixumab beta the only approved immunotherapy in Europe for high risk neuroblastoma and an important tool in the fight against the condition.
